XBiotech Announces Enrollment Completion Of Phase II, Placebo Controlled, Multicenter Study For Natrunix In Pancreatic Cancer
XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase I/II randomized, double-blind, placebo-controlled clinical study for Natrunix in combination with